Hercules Capital, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED SCHEDULE OF INVESTMENTS

CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands, $ in Thousands		Dec. 31, 2022 USD ($) shares		Dec. 31, 2022 GBP (£) shares		Dec. 31, 2021 USD ($) shares		Dec. 31, 2021 GBP (£) shares
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		7.50%		7.50%
Investment cost		$ 3,005,696				$ 2,390,984
Total investments at fair value		2,963,955				2,434,522
Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^[1]					2,032
Total investments at fair value		3,893				1,814
Senior Secured Debt
Investment Holdings [Line Items]
Total investments at fair value		2,741,388				2,156,709
Unsecured
Investment Holdings [Line Items]
Total investments at fair value		54,056				52,890
Debt Investments
Investment Holdings [Line Items]
Investment cost		2,818,060	^[2]			2,219,586	^[1]
Total investments at fair value		2,795,444				2,209,599
Equity
Investment Holdings [Line Items]
Investment cost		153,173	^[2]			142,219
Total investments at fair value		133,972				184,710
Equity \| Preferred Stock
Investment Holdings [Line Items]
Total investments at fair value		41,488				69,439
Equity \| Common Stock
Investment Holdings [Line Items]
Total investments at fair value		92,484				115,271
Warrant Investment
Investment Holdings [Line Items]
Investment cost		30,964	^[2]			27,147	^[1]
Total investments at fair value		30,646				38,399
Investments in Securities
Investment Holdings [Line Items]
Investment cost		3,002,197	^[2]			2,388,952	^[1]
Total investments at fair value		2,960,062				2,432,708
Investment
Investment Holdings [Line Items]
Investment cost		3,005,696	^[2]			2,390,984	^[1]
Total investments at fair value		2,963,955				2,434,522
Forbion Growth Opportunities Fund I C V \| Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^{[1],[3],[4],[5]}					2,032
Total investments at fair value	^[3],[4],[5]					$ 1,814
Acquisition Date	^[6]					Nov. 16, 2020		Nov. 16, 2020
Black Crow AI, Inc. affiliates
Investment Holdings [Line Items]
Principal Amount						$ 3,000
Medrobotics Corporation [Member] \| Warrant Investment \| Preferred Series E
Investment Holdings [Line Items]
Acquisition Date	^[6]					Mar. 13, 2013		Mar. 13, 2013
Biotechnology Tools
Investment Holdings [Line Items]
Total investments at fair value		32,825				$ 0
Biotechnology Tools \| Debt Investments
Investment Holdings [Line Items]
Investment cost	^[2]	32,339
Total investments at fair value		32,339
Biotechnology Tools \| Warrant Investment
Investment Holdings [Line Items]
Investment cost	^[2]	485
Total investments at fair value		$ 486
Biotechnology Tools \| Alamar Biosciences, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-06		2026-06
Investment Interest Rate Floor	^[7]	6.50%		6.50%
Investment Interest Rate Paid in Kind	^[7]	1.00%		1.00%
Principal Amount	^[8]	$ 5,000
Investment cost	^[2],[8]	4,951
Total investments at fair value	^[8]	$ 4,951
Biotechnology Tools \| Alamar Biosciences, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	5.95%		5.95%
Biotechnology Tools \| Alamar Biosciences, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	3.00%		3.00%
Biotechnology Tools \| Alamar Biosciences, Inc. \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost	^[2]	$ 24
Total investments at fair value		$ 23
Acquisition Date	^[9]	Jun. 21, 2022		Jun. 21, 2022
Shares \| shares		15,399		15,399
Biotechnology Tools \| PathAI, Inc \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-01		2027-01
Investment Interest Rate Floor	^[7]	9.15%		9.15%
Principal Amount	^[8]	$ 28,000
Investment cost	^[2],[8]	27,388
Total investments at fair value	^[8]	$ 27,388
Biotechnology Tools \| PathAI, Inc \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	11.21%		11.21%
Biotechnology Tools \| PathAI, Inc \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	2.15%		2.15%
Biotechnology Tools \| PathAI, Inc \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 461
Total investments at fair value		$ 463
Acquisition Date	^[9]	Dec. 23, 2022		Dec. 23, 2022
Shares \| shares		53,418		53,418
Communications & Networking
Investment Holdings [Line Items]
Total investments at fair value		$ 101,833				105,490
Communications & Networking \| Debt Investments
Investment Holdings [Line Items]
Investment cost		99,167	^[2]			97,088	^[1]
Total investments at fair value		101,734				99,230
Communications & Networking \| Equity
Investment Holdings [Line Items]
Investment cost	^[1]					1,230
Total investments at fair value						6,260
Communications & Networking \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		541	^[2]			418
Total investments at fair value		$ 99				$ 0
Communications & Networking \| Aryaka Networks, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-07		2026-07
Investment Interest Rate Floor	^[7]	6.75%		6.75%
Investment Interest Rate Paid in Kind	^[7]	1.05%		1.05%
Principal Amount	^{[8],[10],[11]}	$ 5,023
Investment cost	^{[2],[8],[10],[11]}	4,969
Total investments at fair value	^{[8],[10],[11]}	$ 5,053
Communications & Networking \| Aryaka Networks, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	3.55%		3.55%
Communications & Networking \| Aryaka Networks, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	3.25%		3.25%
Communications & Networking \| Aryaka Networks, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 123
Total investments at fair value		$ 99
Acquisition Date	^[9]	Jun. 28, 2022		Jun. 28, 2022
Shares \| shares		229,611		229,611
Communications & Networking \| Cytracom Holdings LLC \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2025-02		2025-02		2025-02		2025-02
Investment Interest Rate Floor		10.31%	^[7]	10.31%	^[7]	10.31%	^[12]	10.31%	^[12]
Principal Amount		$ 8,910	^{[8],[13],[14]}			$ 9,000	^{[3],[15],[16]}
Investment cost		8,768	^{[2],[8],[13],[14]}			8,802	^{[1],[3],[15],[16]}
Total investments at fair value		$ 8,748	^{[8],[13],[14]}			$ 8,725	^{[3],[15],[16]}
Communications & Networking \| Cytracom Holdings LLC \| Senior Secured Debt \| LIBOR
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		9.31%	^[7]	9.31%	^[7]	9.31%	^[12]	9.31%	^[12]
Communications & Networking \| Spring Mobile Solutions, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 418	^[2]			$ 418
Total investments at fair value						$ 0
Acquisition Date		Apr. 19, 2013	^[9]	Apr. 19, 2013	^[9]	Apr. 19, 2013	^[6]	Apr. 19, 2013	^[6]
Shares \| shares		2,834,375		2,834,375		2,834,375		2,834,375
Communications & Networking \| Rocket Lab Global Services, LLC \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-06		2024-06		2024-06		2024-06
Investment Interest Rate Floor		8.15%	^[7]	8.15%	^[7]	8.15%	^[12]	8.15%	^[12]
Investment Interest Rate Paid in Kind		1.25%	^[7]	1.25%	^[7]	1.25%	^[12]	1.25%	^[12]
Principal Amount		$ 84,581	^{[11],[13],[17],[18],[19]}			$ 88,542	^[20],[21]
Investment cost		85,430	^{[2],[11],[13],[17],[18],[19]}			88,286	^{[1],[20],[21]}
Total investments at fair value		$ 87,933	^{[11],[13],[17],[18],[19]}			$ 90,505	^[20],[21]
Communications & Networking \| Rocket Lab Global Services, LLC \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		3.25%	^[7]	3.25%	^[7]	3.25%	^[12]	3.25%	^[12]
Communications & Networking \| Rocket Lab Global Services, LLC \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		4.90%	^[7]	4.90%	^[7]	4.90%	^[12]	4.90%	^[12]
Communications & Networking \| Peerless Network Holdings, Inc. \| Equity
Investment Holdings [Line Items]
Investment cost	^[1]					$ 1,230
Total investments at fair value						$ 6,260
Shares \| shares						1,138,328		1,138,328
Communications & Networking \| Peerless Network Holdings, Inc. \| Equity \| Preferred Series A
Investment Holdings [Line Items]
Investment cost	^[1]					$ 1,230
Total investments at fair value						$ 6,242
Acquisition Date	^[6]					Apr. 11, 2008		Apr. 11, 2008
Shares \| shares						1,135,000		1,135,000
Communications & Networking \| Peerless Network Holdings, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1]					$ 0
Total investments at fair value						$ 18
Acquisition Date	^[6]					Oct. 21, 2020		Oct. 21, 2020
Shares \| shares						3,328		3,328
Consumer & Business Products
Investment Holdings [Line Items]
Total investments at fair value		$ 2,821				$ 28,099
Consumer & Business Products \| Debt Investments
Investment Holdings [Line Items]
Investment cost	^[1]					23,162
Total investments at fair value						23,298
Consumer & Business Products \| Equity
Investment Holdings [Line Items]
Investment cost		663	^[2]			128	^[1]
Total investments at fair value		498				447
Consumer & Business Products \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		1,712	^[2]			2,145	^[1]
Total investments at fair value		2,323				4,354
Consumer & Business Products \| TechStyle, Inc. \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost	^[2]	1,101
Total investments at fair value		$ 745
Acquisition Date	^[9]	Jul. 16, 2013		Jul. 16, 2013
Shares \| shares		206,185		206,185
Consumer & Business Products \| Whoop, Inc. \| Warrant Investment \| Preferred Series C
Investment Holdings [Line Items]
Investment cost		$ 18	^[2]			18	^[1]
Total investments at fair value		$ 475				$ 1,847
Acquisition Date		Jun. 27, 2018	^[9]	Jun. 27, 2018	^[9]	Jun. 27, 2018	^[6]	Jun. 27, 2018	^[6]
Shares \| shares		686,270		686,270		686,270		686,270
Consumer & Business Products \| The Neat Company \| Common Stock \| Preferred Series C
Investment Holdings [Line Items]
Total investments at fair value						$ 0
Consumer & Business Products \| The Neat Company \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 365	^[2]			$ 365	^[1]
Total investments at fair value
Acquisition Date		Aug. 13, 2014	^[9]	Aug. 13, 2014	^[9]	Aug. 13, 2014	^[6]	Aug. 13, 2014	^[6]
Shares \| shares		54,054		54,054		54,054		54,054
Consumer & Business Products \| Grove Collaborative, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date						2025-04		2025-04
Investment Interest Rate Floor	^[12]					8.75%		8.75%
Principal Amount	^[22]					$ 23,520
Investment cost	^[1],[22]					23,162
Total investments at fair value	^[22]					$ 23,298
Consumer & Business Products \| Grove Collaborative, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[12]					6.75%		6.75%
Consumer & Business Products \| Grove Collaborative, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[12]					5.50%		5.50%
Consumer & Business Products \| Grove Collaborative, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 433
Total investments at fair value	^[9]	$ 24
Acquisition Date	^[9]	Apr. 30, 2021		Apr. 30, 2021
Shares \| shares	^[9]	61,300		61,300
Consumer & Business Products \| Grove Collaborative, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1]					$ 433
Total investments at fair value						$ 326
Acquisition Date	^[6]					Apr. 30, 2021		Apr. 30, 2021
Shares \| shares						83,625		83,625
Consumer & Business Products \| Penumbra Brands, LLC (p.k.a. Gadget Guard) \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1]					$ 228
Total investments at fair value						$ 0
Acquisition Date	^[6]					Jun. 03, 2014		Jun. 03, 2014
Shares \| shares						1,662,441		1,662,441
Consumer & Business Products \| TFG Holding, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 89
Total investments at fair value		$ 116
Acquisition Date	^[9]	Apr. 30, 2010		Apr. 30, 2010
Shares \| shares		42,989		42,989
Consumer & Business Products \| TFG Holding, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 0
Total investments at fair value
Acquisition Date	^[9]	Jun. 27, 2014		Jun. 27, 2014
Shares \| shares		206,185		206,185
Consumer & Business Products \| Savage X Holding, LLC \| Equity \| Class A Units
Investment Holdings [Line Items]
Investment cost	^[2]	$ 13
Total investments at fair value		$ 226
Acquisition Date	^[9]	Apr. 30, 2010		Apr. 30, 2010
Shares \| shares		42,137		42,137
Consumer & Business Products \| Savage X Holding, LLC \| Warrant Investment \| Class A Units
Investment Holdings [Line Items]
Investment cost	^[2]	$ 0
Total investments at fair value		$ 1,103
Acquisition Date	^[9]	Jun. 27, 2014		Jun. 27, 2014
Shares \| shares		206,185		206,185
Consumer & Business Products \| TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 128	^[2]			$ 128	^[1]
Total investments at fair value		$ 132				$ 447
Acquisition Date		Apr. 30, 2010	^[9]	Apr. 30, 2010	^[9]	Apr. 30, 2010	^[6]	Apr. 30, 2010	^[6]
Shares \| shares		42,989		42,989		42,989		42,989
Consumer & Business Products \| TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost	^[1]					$ 1,101
Total investments at fair value						$ 2,181
Acquisition Date	^[6]					Jul. 16, 2013		Jul. 16, 2013
Shares \| shares						206,185		206,185
Consumer & Business Products \| Gadget Guard, LLC \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 228
Total investments at fair value
Acquisition Date	^[9]	Jun. 03, 2014		Jun. 03, 2014
Shares \| shares		1,662,441		1,662,441
Consumer & Business Services \| Debt Investments
Investment Holdings [Line Items]
Investment cost	^[2]	$ 444,703
Total investments at fair value		428,750
Consumer & Business Services \| Equity
Investment Holdings [Line Items]
Investment cost	^[2]	13,488
Total investments at fair value		7,995
Consumer & Business Services \| Warrant Investment
Investment Holdings [Line Items]
Investment cost	^[2]	4,248
Total investments at fair value		$ 2,639
Consumer & Business Services \| Jobandtalent USA, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2025-02		2025-02
Investment Interest Rate Floor	^[7]	9.75%		9.75%
Principal Amount	^[23],[24]	$ 14,000
Investment cost	^{[2],[23],[24]}	13,853
Total investments at fair value	^[23],[24]	$ 13,904
Consumer & Business Services \| Jobandtalent USA, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	3.00%		3.00%
Consumer & Business Services \| Jobandtalent USA, Inc. \| Senior Secured Debt \| SOFR
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	8.86%		8.86%
Consumer & Business Services \| Provi \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-12		2026-12
Investment Interest Rate Floor	^[7]	10.65%		10.65%
Principal Amount	^[25]	$ 15,000
Investment cost	^[2],[25]	14,739
Total investments at fair value	^[25]	$ 14,739
Consumer & Business Services \| Provi \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	2.95%		2.95%
Consumer & Business Services \| Provi \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.40%		4.40%
Consumer & Business Services \| Provi \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[25]	$ 166
Total investments at fair value	^[25]	$ 155
Acquisition Date	^[9]	Dec. 22, 2022		Dec. 22, 2022
Shares \| shares	^[25]	117,042		117,042
Consumer & Business Services \| Veem, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2025-03		2025-03
Investment Interest Rate Floor	^[7]	7.25%		7.25%
Investment Interest Rate Paid in Kind	^[7]	1.25%		1.25%
Principal Amount	^[11],[17]	$ 5,043
Investment cost	^{[2],[11],[17]}	5,000
Total investments at fair value	^[11],[17]	$ 5,042
Consumer & Business Services \| Veem, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	4.50%		4.50%
Consumer & Business Services \| Veem, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.00%		4.00%
Consumer & Business Services \| Veem, Inc. \| Debt Investments
Investment Holdings [Line Items]
Principal Amount		$ 10,076
Investment cost	^[2]	9,988
Total investments at fair value		10,166
Consumer & Business Services \| Veem, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	126
Total investments at fair value		$ 25
Acquisition Date	^[9]	Mar. 31, 2022		Mar. 31, 2022
Shares \| shares		98,428		98,428
Consumer & Business Services \| Veem, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2025-03		2025-03
Investment Interest Rate Floor	^[7]	7.95%		7.95%
Investment Interest Rate Paid in Kind	^[7]	1.50%		1.50%
Principal Amount	^[11]	$ 5,033
Investment cost	^[2],[11]	4,988
Total investments at fair value	^[11]	$ 5,124
Consumer & Business Services \| Veem, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	4.50%		4.50%
Consumer & Business Services \| Veem, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.70%		4.70%
Consumer & Business Services \| RVShare, LLC \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-12		2026-12
Investment Interest Rate Floor	^[7]	6.50%		6.50%
Investment Interest Rate Paid in Kind	^[7]	4.00%		4.00%
Principal Amount	^{[8],[11],[17],[25]}	$ 27,730
Investment cost	^{[2],[8],[11],[17],[25]}	27,265
Total investments at fair value	^{[8],[11],[17],[25]}	$ 27,256
Consumer & Business Services \| RVShare, LLC \| Senior Secured Debt \| LIBOR
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	5.50%		5.50%
Consumer & Business Services \| Snagajobcom Inc \| Warrant Investment
Investment Holdings [Line Items]
Investment cost	^[2]	$ 860
Total investments at fair value		$ 118
Shares \| shares		3,611,537		3,611,537
Consumer & Business Services \| Snagajobcom Inc \| Warrant Investment \| Preferred Series A
Investment Holdings [Line Items]
Investment cost	^[2]	$ 782
Total investments at fair value		$ 50
Acquisition Date	^[9]	Jun. 30, 2016		Jun. 30, 2016
Shares \| shares		1,800,000		1,800,000
Consumer & Business Services \| Snagajobcom Inc \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost	^[2]	$ 62
Total investments at fair value		$ 25
Acquisition Date	^[9]	Aug. 01, 2018		Aug. 01, 2018
Shares \| shares		1,211,537		1,211,537
Consumer & Business Services \| Snagajobcom Inc \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 16
Total investments at fair value		$ 43
Acquisition Date	^[9]	Apr. 20, 2020		Apr. 20, 2020
Shares \| shares		600,000		600,000
Consumer & Business Services \| RumbleON, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 88
Total investments at fair value	^[9]	$ 0
Acquisition Date	^[9]	Apr. 30, 2018		Apr. 30, 2018
Shares \| shares	^[9]	5,139		5,139
Consumer & Business Services \| Lendio, Inc. \| Warrant Investment \| Preferred Series D
Investment Holdings [Line Items]
Investment cost	^[2]	$ 39
Total investments at fair value		$ 19
Acquisition Date	^[9]	Mar. 29, 2019		Mar. 29, 2019
Shares \| shares		127,032		127,032
Consumer & Business Services \| Landing Holdings Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[25]	$ 116
Total investments at fair value	^[25]	$ 127
Acquisition Date	^[9]	Mar. 12, 2021		Mar. 12, 2021
Shares \| shares	^[25]	11,806		11,806
Consumer & Business Services \| Lyft Inc \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 5,263
Total investments at fair value	^[9]	$ 1,110
Acquisition Date	^[9]	Dec. 26, 2018		Dec. 26, 2018
Shares \| shares	^[9]	100,738		100,738
Consumer & Business Services \| Uber Technologies, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 318
Total investments at fair value	^[9]	$ 816
Acquisition Date	^[9]	Dec. 01, 2020		Dec. 01, 2020
Shares \| shares	^[9]	32,991		32,991
Consumer & Business Services \| Nerdy Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 1,000
Total investments at fair value	^[9]	$ 225
Acquisition Date	^[9]	Sep. 17, 2021		Sep. 17, 2021
Shares \| shares	^[9]	100,000		100,000
Consumer & Business Services \| DoorDash, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 945
Total investments at fair value	^[9]	$ 4,003
Acquisition Date	^[9]	Dec. 20, 2018		Dec. 20, 2018
Shares \| shares	^[9]	81,996		81,996
Consumer & Business Services \| OfferUp, Inc. \| Equity
Investment Holdings [Line Items]
Investment cost	^[2]	$ 2,295
Total investments at fair value		$ 513
Shares \| shares		394,790		394,790
Consumer & Business Services \| OfferUp, Inc. \| Equity \| Preferred Series A
Investment Holdings [Line Items]
Investment cost	^[2]	$ 1,663
Total investments at fair value		$ 372
Acquisition Date	^[9]	Oct. 25, 2016		Oct. 25, 2016
Shares \| shares		286,080		286,080
Consumer & Business Services \| OfferUp, Inc. \| Equity \| Preferred Series A-1
Investment Holdings [Line Items]
Investment cost	^[2]	$ 632
Total investments at fair value		$ 141
Acquisition Date	^[9]	Oct. 25, 2016		Oct. 25, 2016
Shares \| shares		108,710		108,710
Consumer & Business Services \| Oportun \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 577
Total investments at fair value	^[9]	$ 266
Acquisition Date	^[9]	Jun. 28, 2013		Jun. 28, 2013
Shares \| shares	^[9]	48,365		48,365
Consumer & Business Services \| Reischling Press, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 39
Total investments at fair value
Acquisition Date	^[9]	Jul. 31, 2020		Jul. 31, 2020
Shares \| shares		3,095		3,095
Consumer & Business Services \| App Direct Incorporation \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-04		2026-04
Investment Interest Rate Floor	^[7]	8.75%		8.75%
Principal Amount	^[8],[18]	$ 40,790
Investment cost	^[2],[8],[18]	41,856
Total investments at fair value	^[8],[18]	$ 42,426
Consumer & Business Services \| App Direct Incorporation \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	8.29%		8.29%
Consumer & Business Services \| App Direct Incorporation \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	5.50%		5.50%
Consumer & Business Services \| Carwow LTD \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-12		2024-12
Investment Interest Rate Floor	^[7]	7.95%		7.95%
Investment Interest Rate Paid in Kind	^[7]	1.45%		1.45%
Principal Amount \| £	^{[11],[23],[24]}			£ 18,890
Investment cost	^{[2],[11],[23],[24]}	$ 26,024
Total investments at fair value	^{[11],[23],[24]}	$ 22,971
Consumer & Business Services \| Carwow LTD \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	4.95%		4.95%
Consumer & Business Services \| Carwow LTD \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.70%		4.70%
Consumer & Business Services \| Carwow LTD \| Equity \| Preferred Series D-4
Investment Holdings [Line Items]
Investment cost	^{[2],[23],[24]}	$ 1,151
Total investments at fair value	^[23],[24]	$ 257
Acquisition Date	^[9]	Dec. 15, 2021		Dec. 15, 2021
Shares \| shares	^[23],[24]	199,742		199,742
Consumer & Business Services \| Carwow LTD \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^{[2],[23],[24]}	$ 164
Total investments at fair value	^[23],[24]	$ 34
Acquisition Date	^[9]	Dec. 14, 2021		Dec. 14, 2021
Shares \| shares	^[23],[24]	174,163		174,163
Consumer & Business Services \| Houzz, Inc. \| Convertible Debt
Investment Holdings [Line Items]
Maturity Date		2028-05		2028-05
Investment Interest Rate Paid in Kind	^[7]	5.50%		5.50%
Principal Amount	^[11],[26]	$ 21,853
Investment cost	^{[2],[11],[26]}	21,853
Total investments at fair value	^[11],[26]	20,356
Consumer & Business Services \| Houzz, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	20
Total investments at fair value
Acquisition Date	^[9]	Oct. 29, 2019		Oct. 29, 2019
Shares \| shares		529,661		529,661
Consumer & Business Services \| Rhino Labs Incorporation \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-03		2024-03
Investment Interest Rate Floor	^[7]	8.75%		8.75%
Investment Interest Rate Paid in Kind	^[7]	2.25%		2.25%
Principal Amount	^[11],[25]	$ 16,500
Investment cost	^{[2],[11],[25]}	16,328
Total investments at fair value	^[11],[25]	$ 16,496
Consumer & Business Services \| Rhino Labs Incorporation \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	5.50%		5.50%
Consumer & Business Services \| Rhino Labs Incorporation \| Equity \| Preferred Series B-2
Investment Holdings [Line Items]
Investment cost	^[2]	$ 1,000
Total investments at fair value		$ 805
Acquisition Date	^[9]	Jan. 24, 2022		Jan. 24, 2022
Shares \| shares		7,063		7,063
Consumer & Business Services \| Rhino Labs Incorporation \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[25]	$ 470
Total investments at fair value	^[25]	$ 308
Acquisition Date	^[9]	Mar. 12, 2021		Mar. 12, 2021
Shares \| shares	^[25]	13,106		13,106
Consumer & Business Services \| SeatGeek, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2023-06		2023-06
Investment Interest Rate Floor	^[7]	10.50%		10.50%
Investment Interest Rate Paid in Kind	^[7]	0.50%		0.50%
Principal Amount	^{[11],[17],[18],[19]}	$ 60,915
Investment cost	^{[2],[11],[17],[18],[19]}	60,721
Total investments at fair value	^{[11],[17],[18],[19]}	$ 60,721
Consumer & Business Services \| SeatGeek, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	5.00%		5.00%
Consumer & Business Services \| SeatGeek, Inc. \| Debt Investments
Investment Holdings [Line Items]
Principal Amount		$ 85,986
Investment cost	^[2]	85,633
Total investments at fair value		86,544
Consumer & Business Services \| SeatGeek, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^{[2],[18],[19]}	842
Total investments at fair value	^[18],[19]	$ 1,332
Acquisition Date	^[9]	Jun. 12, 2019		Jun. 12, 2019
Shares \| shares	^[18],[19]	1,379,761		1,379,761
Consumer & Business Services \| SeatGeek, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-05		2026-05
Investment Interest Rate Floor	^[7]	10.50%		10.50%
Investment Interest Rate Paid in Kind	^[7]	0.50%		0.50%
Principal Amount	^{[11],[13],[19]}	$ 25,071
Investment cost	^{[2],[11],[13],[19]}	24,912
Total investments at fair value	^{[11],[13],[19]}	$ 25,823
Consumer & Business Services \| SeatGeek, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	7.00%		7.00%
Consumer & Business Services \| Skyword, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-11		2026-11
Investment Interest Rate Floor	^[7]	9.25%		9.25%
Investment Interest Rate Paid in Kind	^[7]	1.75%		1.75%
Principal Amount	^[11],[17]	$ 9,007
Investment cost	^{[2],[11],[17]}	8,918
Total investments at fair value	^[11],[17]	$ 8,870
Consumer & Business Services \| Skyword, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	3.00%		3.00%
Consumer & Business Services \| Skyword, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	2.75%		2.75%
Consumer & Business Services \| Skyword, Inc. \| Warrant Investment
Investment Holdings [Line Items]
Investment cost	^[2]	$ 140
Total investments at fair value		$ 43
Shares \| shares		2,051,587		2,051,587
Consumer & Business Services \| Skyword, Inc. \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost	^[2]	$ 83
Total investments at fair value
Acquisition Date	^[9]	Aug. 23, 2019		Aug. 23, 2019
Shares \| shares		444,444		444,444
Consumer & Business Services \| Skyword, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]	$ 57
Total investments at fair value		$ 43
Acquisition Date	^[9]	Nov. 14, 2022		Nov. 14, 2022
Shares \| shares		1,607,143		1,607,143
Consumer & Business Services \| Tectura Corporation \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-07		2024-07
Investment Interest Rate Paid in Kind	^[7]	5.00%		5.00%
Principal Amount	^{[11],[27],[28]}	$ 10,680
Investment cost	^{[2],[11],[27],[28]}	240
Total investments at fair value	^{[11],[27],[28]}	0
Consumer & Business Services \| Tectura Corporation \| Debt Investments
Investment Holdings [Line Items]
Principal Amount		31,953
Investment cost	^[2]	21,513
Total investments at fair value		$ 8,042
Consumer & Business Services \| Tectura Corporation \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-07		2024-07
Principal Amount	^{[11],[27],[28]}	$ 8,250
Investment Interest Rate Paid in Cash	^[7]	8.25%		8.25%
Investment cost	^{[2],[11],[27],[28]}	$ 8,250
Total investments at fair value	^{[11],[27],[28]}	$ 8,042
Consumer & Business Services \| Tectura Corporation \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-07		2024-07
Investment Interest Rate Paid in Kind	^[7]	5.00%		5.00%
Principal Amount	^{[11],[27],[28]}	$ 13,023
Investment cost	^{[2],[11],[27],[28]}	13,023
Total investments at fair value	^{[11],[27],[28]}	0
Consumer & Business Services \| Tectura Corporation \| Equity
Investment Holdings [Line Items]
Investment cost	^[2]	900
Total investments at fair value
Shares \| shares		415,994,863		415,994,863
Consumer & Business Services \| Tectura Corporation \| Equity \| Preferred Series BB
Investment Holdings [Line Items]
Investment cost	^[27]	$ 0
Total investments at fair value	^[27]	$ 0
Acquisition Date	^[9]	Jun. 06, 2016		Jun. 06, 2016
Shares \| shares	^[27]	1,000,000		1,000,000
Consumer & Business Services \| Tectura Corporation \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[27]	$ 900
Total investments at fair value	^[27]	$ 0
Acquisition Date	^[9]	May 23, 2018		May 23, 2018
Shares \| shares	^[27]	414,994,863		414,994,863
Consumer & Business Services \| Thumbtack, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-04		2026-04
Investment Interest Rate Floor	^[7]	8.20%		8.20%
Investment Interest Rate Paid in Kind	^[7]	1.50%		1.50%
Principal Amount	^{[8],[11],[18]}	$ 10,103
Investment cost	^{[2],[8],[11],[18]}	10,050
Total investments at fair value	^{[8],[11],[18]}	$ 10,167
Consumer & Business Services \| Thumbtack, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	3.95%		3.95%
Consumer & Business Services \| Thumbtack, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.95%		4.95%
Consumer & Business Services \| Thumbtack, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[18]	$ 844
Total investments at fair value	^[18]	$ 280
Acquisition Date	^[9]	May 01, 2018		May 01, 2018
Shares \| shares	^[18]	267,225		267,225
Consumer & Business Services \| Worldremit Group Limited \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2025-02		2025-02
Investment Interest Rate Floor	^[7]	10.25%		10.25%
Principal Amount	^{[10],[13],[18],[19],[23],[24]}	$ 94,500
Investment cost	^{[2],[10],[13],[18],[19],[23],[24]}	94,418
Total investments at fair value	^{[10],[13],[18],[19],[23],[24]}	$ 93,837
Consumer & Business Services \| Worldremit Group Limited \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	3.00%		3.00%
Consumer & Business Services \| Worldremit Group Limited \| Senior Secured Debt \| LIBOR
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	9.25%		9.25%
Consumer & Business Services \| Worldremit Group Limited \| Warrant Investment
Investment Holdings [Line Items]
Investment cost	^[2]	$ 155
Total investments at fair value		$ 194
Shares \| shares		79,083		79,083
Consumer & Business Services \| Worldremit Group Limited \| Warrant Investment \| Preferred Series D
Investment Holdings [Line Items]
Investment cost	^{[2],[18],[19],[23],[24]}	$ 129
Total investments at fair value	^{[18],[19],[23],[24]}	$ 192
Acquisition Date	^[9]	Feb. 11, 2021		Feb. 11, 2021
Shares \| shares	^{[18],[19],[23],[24]}	77,215		77,215
Consumer & Business Services \| Worldremit Group Limited \| Warrant Investment \| Preferred Series E
Investment Holdings [Line Items]
Investment cost	^{[2],[19],[23],[24]}	$ 26
Total investments at fair value	^{[19],[23],[24]}	$ 2
Acquisition Date	^[9]	Aug. 27, 2021		Aug. 27, 2021
Shares \| shares	^{[19],[23],[24]}	1,868		1,868
Consumer & Business Services \| Udacity, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-09		2024-09
Investment Interest Rate Floor	^[7]	7.75%		7.75%
Investment Interest Rate Paid in Kind	^[7]	2.00%		2.00%
Principal Amount	^[11],[18]	$ 51,937
Investment cost	^{[2],[11],[18]}	52,265
Total investments at fair value	^[11],[18]	$ 52,976
Consumer & Business Services \| Udacity, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	3.00%		3.00%
Consumer & Business Services \| Udacity, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.50%		4.50%
Consumer & Business Services \| Udacity, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[18]	$ 218
Total investments at fair value	^[18]	$ 4
Acquisition Date	^[9]	Sep. 25, 2020		Sep. 25, 2020
Shares \| shares	^[18]	486,359		486,359
Diversified Financial Services
Investment Holdings [Line Items]
Total investments at fair value		$ 68,569				$ 65,073
Diversified Financial Services \| Debt Investments
Investment Holdings [Line Items]
Investment cost		36,567	^[2]			33,738	^[1]
Total investments at fair value		33,700				32,465
Diversified Financial Services \| Equity
Investment Holdings [Line Items]
Investment cost		28,444	^[2]			28,041	^[1]
Total investments at fair value		$ 34,869				$ 32,608
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Unsecured
Investment Holdings [Line Items]
Maturity Date		2026-09		2026-09		2026-09		2026-09
Principal Amount		$ 15,000	^[27]			$ 15,000	^[29]
Investment Interest Rate Paid in Cash		14.50%	^[7]	14.50%	^[7]	14.50%	^[12]	14.50%	^[12]
Investment cost		$ 14,715	^[2],[27]			$ 14,662	^[1],[29]
Total investments at fair value		12,802	^[27]			13,818	^[29]
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Debt Investments
Investment Holdings [Line Items]
Principal Amount		25,000				25,000
Investment cost		24,567	^[2]			24,485	^[1]
Total investments at fair value		21,700				23,212
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Equity
Investment Holdings [Line Items]
Investment cost		28,006	^[2]			28,006	^[1]
Total investments at fair value		$ 15,244				$ 20,618
Shares \| shares		11,432,752		11,432,752		11,432,752		11,432,752
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Equity \| Preferred Series A
Investment Holdings [Line Items]
Investment cost	^[2],[27]	$ 26,122
Total investments at fair value	^[27]	$ 14,137
Acquisition Date	^[9]	Mar. 01, 2018		Mar. 01, 2018
Shares \| shares	^[27]	10,602,752		10,602,752
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,884	^[2],[27]			$ 1,884	^[1],[29]
Total investments at fair value		$ 1,107	^[27]			$ 1,225	^[29]
Acquisition Date		Mar. 01, 2018	^[9]	Mar. 01, 2018	^[9]	Mar. 01, 2018	^[6]	Mar. 01, 2018	^[6]
Shares \| shares		830,000	^[27]	830,000	^[27]	830,000	^[29]	830,000	^[29]
Diversified Financial Services \| Gibraltar Business Capital L L C One \| Unsecured
Investment Holdings [Line Items]
Maturity Date		2026-09		2026-09		2026-09		2026-09
Principal Amount		$ 10,000	^[27]			$ 10,000	^[29]
Investment Interest Rate Paid in Cash		11.50%	^[7]	11.50%	^[7]	11.50%	^[12]	11.50%	^[12]
Investment cost		$ 9,852	^[2],[27]			$ 9,823	^[1],[29]
Total investments at fair value		$ 8,898	^[27]			9,394	^[29]
Diversified Financial Services \| Gibraltar Business Capital L L C One \| Equity \| Preferred Series A
Investment Holdings [Line Items]
Investment cost	^[1],[29]					26,122
Total investments at fair value	^[29]					$ 19,393
Acquisition Date	^[6]					Mar. 01, 2018		Mar. 01, 2018
Shares \| shares	^[29]					10,602,752		10,602,752
Diversified Financial Services \| Hercules Adviser LLC \| Unsecured
Investment Holdings [Line Items]
Maturity Date		2025-06		2025-06		2023-05		2023-05
Principal Amount		$ 12,000	^[27]			$ 8,850	^[29]
Investment Interest Rate Paid in Cash		5.00%	^[7]	5.00%	^[7]	5.00%	^[12]	5.00%	^[12]
Investment cost		$ 12,000	^[2],[27]			$ 8,850	^[1],[29]
Total investments at fair value		12,000	^[27]			8,850	^[29]
Diversified Financial Services \| Hercules Adviser LLC \| Equity \| Member Units
Investment Holdings [Line Items]
Investment cost		35	^[2],[27]			35	^[1],[29]
Total investments at fair value		$ 19,153	^[27]			$ 11,990	^[29]
Acquisition Date		Mar. 26, 2021	^[9]	Mar. 26, 2021	^[9]	Mar. 26, 2021	^[6]	Mar. 26, 2021	^[6]
Shares \| shares		1	^[27]	1	^[27]	1	^[29]	1	^[29]
Diversified Financial Services \| Newfront Insurance Holdings, Inc. \| Convertible Debt
Investment Holdings [Line Items]
Maturity Date						2022-08		2022-08
Investment Interest Rate Floor	^[12]					0.19%		0.19%
Investment Interest Rate Paid in Kind	^[12]					0.19%		0.19%
Principal Amount	^[30]					$ 403
Investment cost	^[1],[30]					403
Total investments at fair value	^[30]					403
Diversified Financial Services \| Newfront Insurance Holdings, Inc. \| Equity \| Preferred Series D-2
Investment Holdings [Line Items]
Investment cost	^[2]	$ 403
Total investments at fair value		$ 472
Acquisition Date	^[9]	Sep. 30, 2021		Sep. 30, 2021
Shares \| shares		210,282		210,282
Drug Delivery
Investment Holdings [Line Items]
Total investments at fair value		$ 90				368
Drug Delivery \| Equity
Investment Holdings [Line Items]
Investment cost		3,638	^[2]			3,638	^[1]
Total investments at fair value		89				305
Drug Delivery \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		465	^[2]			465	^[1]
Total investments at fair value		1				63
Drug Delivery \| PDS Biotechnology Corporation \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	390
Total investments at fair value	^[9]	$ 1
Acquisition Date	^[9]	Aug. 28, 2014		Aug. 28, 2014
Shares \| shares	^[9]	3,929		3,929
Drug Delivery \| Aerami Therapeutics Holdings, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 74	^[2]			74	^[1]
Total investments at fair value						$ 0
Acquisition Date		Sep. 30, 2015	^[9]	Sep. 30, 2015	^[9]	Sep. 30, 2015	^[6]	Sep. 30, 2015	^[6]
Shares \| shares		110,882		110,882		110,882		110,882
Drug Delivery \| PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 309	^[2],[9]			$ 309	^[1],[6]
Total investments at fair value		$ 33	^[9]			$ 20	^[6]
Acquisition Date		Apr. 06, 2015	^[9]	Apr. 06, 2015	^[9]	Apr. 06, 2015	^[6]	Apr. 06, 2015	^[6]
Shares \| shares		2,498	^[9]	2,498	^[9]	2,498	^[6]	2,498	^[6]
Drug Delivery \| PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[6]					$ 390
Total investments at fair value	^[6]					$ 1
Acquisition Date	^[6]					Aug. 28, 2014		Aug. 28, 2014
Shares \| shares	^[6]					3,929		3,929
Drug Delivery \| BioQ Pharma Incorporated \| Equity \| Preferred Series D
Investment Holdings [Line Items]
Investment cost		$ 500	^[2]			$ 500	^[1]
Total investments at fair value		$ 33				$ 168
Acquisition Date		Dec. 08, 2015	^[9]	Dec. 08, 2015	^[9]	Dec. 08, 2015	^[6]	Dec. 08, 2015	^[6]
Shares \| shares		165,000		165,000		165,000		165,000
Drug Delivery \| BioQ Pharma Incorporated \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1	^[2]			$ 1	^[1]
Total investments at fair value						$ 62
Acquisition Date		Oct. 27, 2014	^[9]	Oct. 27, 2014	^[9]	Oct. 27, 2014	^[6]	Oct. 27, 2014	^[6]
Shares \| shares		459,183		459,183		459,183		459,183
Drug Delivery \| Aytu BioScience, Inc. (p.k.a. Neos Therapeutics, Inc.) \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,500	^[2],[9]			$ 1,500	^[1],[6]
Total investments at fair value		$ 3	^[9]			$ 18	^[6]
Acquisition Date		Mar. 28, 2014	^[9]	Mar. 28, 2014	^[9]	Mar. 28, 2014	^[6]	Mar. 28, 2014	^[6]
Shares \| shares		13,600	^[9]	13,600	^[9]	13,600	^[6]	13,600	^[6]
Drug Delivery \| AcelRx Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,329	^[2],[9]			$ 1,329	^[1],[6]
Total investments at fair value		$ 20	^[9]			$ 99	^[6]
Acquisition Date		Dec. 10, 2018	^[9]	Dec. 10, 2018	^[9]	Dec. 10, 2018	^[6]	Dec. 10, 2018	^[6]
Shares \| shares		8,836	^[9]	8,836	^[9]	176,730	^[6]	176,730	^[6]
Drug Discovery & Development
Investment Holdings [Line Items]
Total investments at fair value		$ 1,150,707				$ 967,383
Drug Discovery & Development \| Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^[2]	3,118
Total investments at fair value		3,518
Drug Discovery & Development \| Debt Investments
Investment Holdings [Line Items]
Investment cost		1,107,352	^[2]			936,457	^[1]
Total investments at fair value		1,101,430				935,964
Drug Discovery & Development \| Equity
Investment Holdings [Line Items]
Investment cost		43,971	^[2]			33,401	^[1]
Total investments at fair value		37,315				24,860
Drug Discovery & Development \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		7,466	^[2]			7,393	^[1]
Total investments at fair value		8,444				4,745
Drug Discovery & Development \| Forbion Growth Opportunities Fund I I C V \| Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^{[2],[8],[23],[24]}	419
Total investments at fair value	^{[8],[23],[24]}	$ 438
Acquisition Date	^[9]	Jun. 23, 2022		Jun. 23, 2022
Drug Discovery & Development \| Kineta, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 110
Total investments at fair value	^[9]	$ 0
Acquisition Date	^[9]	Dec. 20, 2019		Dec. 20, 2019
Shares \| shares	^[9]	2,202		2,202
Drug Discovery & Development \| Akero Therapeutics, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-01		2027-01
Investment Interest Rate Floor	^[7]	7.65%		7.65%
Principal Amount	^{[8],[17],[23]}	$ 5,000
Investment cost	^{[2],[8],[17],[23]}	4,986
Total investments at fair value	^{[8],[17],[23]}	$ 5,039
Drug Discovery & Development \| Akero Therapeutics, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	5.85%		5.85%
Drug Discovery & Development \| Akero Therapeutics, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	3.65%		3.65%
Drug Discovery & Development \| Akero Therapeutics, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9],[23]	$ 1,000
Total investments at fair value	^[9],[23]	$ 2,108
Acquisition Date	^[9]	Sep. 19, 2022		Sep. 19, 2022
Shares \| shares	^[9],[23]	38,461		38,461
Drug Discovery & Development \| Akero Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9],[23]	$ 56
Total investments at fair value	^[9],[23]	$ 674
Acquisition Date	^[9]	Jun. 15, 2022		Jun. 15, 2022
Shares \| shares	^[9],[23]	18,360		18,360
Drug Discovery & Development \| Alladapt Immunotherapeutics Inc \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-09		2026-09
Investment Interest Rate Floor	^[7]	8.40%		8.40%
Principal Amount	^[8],[17]	$ 15,000
Investment cost	^[2],[8],[17]	14,920
Total investments at fair value	^[8],[17]	$ 14,920
Drug Discovery & Development \| Alladapt Immunotherapeutics Inc \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	10.60%		10.60%
Drug Discovery & Development \| Alladapt Immunotherapeutics Inc \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	10.90%		10.90%
Drug Discovery & Development \| Alladapt Immunotherapeutics Inc \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	3.65%		3.65%
Drug Discovery & Development \| ATAI Life Sciences N.V. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-08		2026-08
Investment Interest Rate Floor	^[7]	8.55%		8.55%
Principal Amount	^[23],[24]	$ 10,500
Investment cost	^{[2],[23],[24]}	10,513
Total investments at fair value	^[23],[24]	$ 10,513
Drug Discovery & Development \| ATAI Life Sciences N.V. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	6.95%		6.95%
Drug Discovery & Development \| ATAI Life Sciences N.V. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.55%		4.55%
Drug Discovery & Development \| Provention Bio, Inc. [Member] \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-09		2027-09
Investment Interest Rate Floor	^[7]	8.20%		8.20%
Principal Amount	^[8]	$ 25,000
Investment cost	^[2],[8]	24,670
Total investments at fair value	^[8]	$ 24,670
Drug Discovery & Development \| Provention Bio, Inc. [Member] \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	6.60%		6.60%
Drug Discovery & Development \| Provention Bio, Inc. [Member] \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	2.70%		2.70%
Drug Discovery & Development \| Provention Bio, Inc. [Member] \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 281
Total investments at fair value	^[9]	$ 677
Acquisition Date	^[9]	Sep. 15, 2022		Sep. 15, 2022
Shares \| shares	^[9]	111,934		111,934
Drug Discovery & Development \| Redshift Bioanalytics, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-01		2026-01
Investment Interest Rate Floor	^[7]	7.50%		7.50%
Principal Amount	^[25]	$ 5,000
Investment cost	^[2],[25]	4,957
Total investments at fair value	^[25]	$ 4,946
Drug Discovery & Development \| Redshift Bioanalytics, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	3.80%		3.80%
Drug Discovery & Development \| Redshift Bioanalytics, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.25%		4.25%
Drug Discovery & Development \| Redshift Bioanalytics, Inc. \| Warrant Investment \| Preferred Series E
Investment Holdings [Line Items]
Investment cost	^[2],[25]	$ 20
Total investments at fair value	^[25]	$ 21
Acquisition Date	^[9]	Mar. 23, 2022		Mar. 23, 2022
Shares \| shares	^[25]	475,510		475,510
Drug Discovery & Development \| Replimune Group, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-10		2027-10
Investment Interest Rate Floor	^[7]	7.25%		7.25%
Investment Interest Rate Paid in Kind	^[7]	1.50%		1.50%
Principal Amount	^{[8],[11],[23]}	$ 20,754
Investment cost	^{[2],[8],[11],[23]}	20,656
Total investments at fair value	^{[8],[11],[23]}	$ 20,656
Drug Discovery & Development \| Replimune Group, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	4.95%		4.95%
Drug Discovery & Development \| Replimune Group, Inc. \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	9.00%		9.00%
Drug Discovery & Development \| Replimune Group, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	1.75%		1.75%
Drug Discovery & Development \| Tarsus Pharmaceuticals, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-02		2027-02
Investment Interest Rate Floor	^[7]	8.45%		8.45%
Principal Amount	^{[8],[17],[23]}	$ 8,250
Investment cost	^{[2],[8],[17],[23]}	8,274
Total investments at fair value	^{[8],[17],[23]}	$ 8,423
Drug Discovery & Development \| Tarsus Pharmaceuticals, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	4.75%		4.75%
Drug Discovery & Development \| Tarsus Pharmaceuticals, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	5.20%		5.20%
Drug Discovery & Development \| Tarsus Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9],[23]	$ 2,100
Total investments at fair value	^[9],[23]	$ 2,280
Acquisition Date	^[9]	May 05, 2022		May 05, 2022
Shares \| shares	^[9],[23]	155,555		155,555
Drug Discovery & Development \| Iveric Bio, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-08		2027-08
Investment Interest Rate Floor	^[7]	8.75%		8.75%
Principal Amount	^[18],[23]	$ 49,500
Investment cost	^{[2],[18],[23]}	49,090
Total investments at fair value	^[18],[23]	$ 49,090
Drug Discovery & Development \| Iveric Bio, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	4.25%		4.25%
Drug Discovery & Development \| Iveric Bio, Inc. \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	10.25%		10.25%
Drug Discovery & Development \| Iveric Bio, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	4.00%		4.00%
Drug Discovery & Development \| AmplifyBio, LLC \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-01		2027-01
Investment Interest Rate Floor	^[7]	9.50%		9.50%
Principal Amount	^[25]	$ 24,000
Investment cost	^[2],[25]	23,663
Total investments at fair value	^[25]	$ 23,663
Drug Discovery & Development \| AmplifyBio, LLC \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	5.85%		5.85%
Drug Discovery & Development \| AmplifyBio, LLC \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	10.75%		10.75%
Drug Discovery & Development \| AmplifyBio, LLC \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	2.50%		2.50%
Drug Discovery & Development \| AmplifyBio, LLC \| Warrant Investment \| Class A Units
Investment Holdings [Line Items]
Investment cost	^[2],[25]	$ 238
Total investments at fair value	^[25]	$ 256
Acquisition Date	^[9]	Dec. 27, 2022		Dec. 27, 2022
Shares \| shares	^[25]	69,239		69,239
Drug Discovery & Development \| HilleVax, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-05		2027-05
Investment Interest Rate Floor	^[7]	4.55%		4.55%
Investment Interest Rate Paid in Kind	^[7]	2.85%		2.85%
Principal Amount	^{[8],[11],[25]}	$ 12,072
Investment cost	^{[2],[8],[11],[25]}	12,043
Total investments at fair value	^{[8],[11],[25]}	$ 11,333
Drug Discovery & Development \| HilleVax, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	7.15%		7.15%
Drug Discovery & Development \| HilleVax, Inc. \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	6.05%		6.05%
Drug Discovery & Development \| HilleVax, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	1.05%		1.05%
Drug Discovery & Development \| HilleVax, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 4,000
Total investments at fair value	^[9]	$ 3,937
Acquisition Date	^[9]	May 03, 2022		May 03, 2022
Shares \| shares	^[9]	235,295		235,295
Drug Discovery & Development \| Kura Oncology, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-11		2027-11
Investment Interest Rate Floor	^[7]	8.65%		8.65%
Principal Amount	^{[8],[23],[25]}	$ 5,500
Investment cost	^{[2],[8],[23],[25]}	5,448
Total investments at fair value	^{[8],[23],[25]}	$ 5,448
Drug Discovery & Development \| Kura Oncology, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	15.13%		15.13%
Drug Discovery & Development \| Kura Oncology, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	2.40%		2.40%
Drug Discovery & Development \| Kura Oncology, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^{[2],[9],[23],[25]}	$ 88
Total investments at fair value	^{[9],[23],[25]}	$ 59
Acquisition Date	^[9]	Nov. 02, 2022		Nov. 02, 2022
Shares \| shares	^{[9],[23],[25]}	14,342		14,342
Drug Discovery & Development \| Madrigal Pharmaceutical, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-05		2026-05
Investment Interest Rate Floor	^[7]	7.45%		7.45%
Principal Amount	^[8],[23]	$ 34,000
Investment cost	^[2],[8],[23]	33,945
Total investments at fair value	^[8],[23]	$ 33,987
Drug Discovery & Development \| Madrigal Pharmaceutical, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	5.35%		5.35%
Drug Discovery & Development \| Madrigal Pharmaceutical, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	3.95%		3.95%
Drug Discovery & Development \| Madrigal Pharmaceutical, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9],[23]	$ 177
Total investments at fair value	^[9],[23]	$ 1,977
Acquisition Date	^[9]	May 09, 2022		May 09, 2022
Shares \| shares	^[9],[23]	10,131		10,131
Drug Discovery & Development \| Forbion Growth Opportunities Fund I C V \| Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^{[2],[8],[23],[24]}	$ 2,699
Total investments at fair value	^{[8],[23],[24]}	$ 3,080
Acquisition Date	^[9]	Nov. 16, 2020		Nov. 16, 2020
Drug Discovery & Development \| Dynavax Technologies \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 550	^[2],[9],[23]			550	^[1],[4],[6]
Total investments at fair value		$ 213	^[9],[23]			$ 281	^[4],[6]
Acquisition Date		Jul. 22, 2015	^[9]	Jul. 22, 2015	^[9]	Jul. 22, 2015	^[6]	Jul. 22, 2015	^[6]
Shares \| shares		20,000	^[9],[23]	20,000	^[9],[23]	20,000	^[4],[6]	20,000	^[4],[6]
Drug Discovery & Development \| Genocea Biosciences Inc \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[6]					$ 2,000
Total investments at fair value	^[6]					$ 32
Acquisition Date	^[6]					Nov. 20, 2014		Nov. 20, 2014
Shares \| shares	^[6]					27,933		27,933
Drug Discovery & Development \| Genocea Biosciences Inc \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[6]					$ 165
Total investments at fair value	^[6]					$ 1
Acquisition Date	^[6]					Apr. 24, 2018		Apr. 24, 2018
Shares \| shares	^[6]					41,176		41,176
Drug Discovery & Development \| NorthSea Therapeutics \| Equity \| Preferred Series C
Investment Holdings [Line Items]
Investment cost		$ 2,000	^{[2],[23],[24]}			$ 2,000	^[1],[4],[5]
Total investments at fair value		$ 1,476	^[23],[24]			$ 2,000	^[4],[5]
Acquisition Date		Dec. 15, 2021	^[9]	Dec. 15, 2021	^[9]	Dec. 15, 2021	^[6]	Dec. 15, 2021	^[6]
Shares \| shares		983	^[23],[24]	983	^[23],[24]	983	^[4],[5]	983	^[4],[5]
Drug Discovery & Development \| Sio Gene Therapies, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,269	^[2],[9]			$ 1,269	^[1],[4],[6]
Total investments at fair value		$ 7	^[9]			$ 21	^[4],[6]
Acquisition Date		Feb. 02, 2017	^[9]	Feb. 02, 2017	^[9]	Feb. 02, 2017	^[6]	Feb. 02, 2017	^[6]
Shares \| shares		16,228	^[9]	16,228	^[9]	16,228	^[4],[6]	16,228	^[4],[6]
Drug Discovery & Development \| Valo Health L L C \| Equity
Investment Holdings [Line Items]
Investment cost	^[2]	$ 4,000
Total investments at fair value		$ 3,075
Shares \| shares		680,410		680,410
Drug Discovery & Development \| Valo Health L L C \| Equity \| Preferred Series B
Investment Holdings [Line Items]
Investment cost		$ 3,000	^[2]			$ 3,000	^[1]
Total investments at fair value		$ 2,063				$ 4,650
Acquisition Date		Dec. 11, 2020	^[9]	Dec. 11, 2020	^[9]	Dec. 11, 2020	^[6]	Dec. 11, 2020	^[6]
Shares \| shares		510,308		510,308		510,308		510,308
Drug Discovery & Development \| Valo Health L L C \| Equity \| Preferred Series C
Investment Holdings [Line Items]
Investment cost	^[2]	$ 1,000
Total investments at fair value		$ 1,012
Acquisition Date	^[9]	Oct. 31, 2022		Oct. 31, 2022
Shares \| shares		170,102		170,102
Drug Discovery & Development \| Paratek Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 2,744	^[2],[9]			$ 2,744	^[1],[6]
Total investments at fair value		$ 143	^[9]			$ 343	^[6]
Acquisition Date		Feb. 26, 2007	^[9]	Feb. 26, 2007	^[9]	Feb. 26, 2007	^[6]	Feb. 26, 2007	^[6]
Shares \| shares		76,362	^[9]	76,362	^[9]	76,362	^[6]	76,362	^[6]
Drug Discovery & Development \| Paratek Pharmaceuticals, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 520	^[2],[9]			$ 546	^[1],[6]
Total investments at fair value		$ 34	^[9]			$ 427	^[6]
Acquisition Date		Aug. 01, 2018	^[9]	Aug. 01, 2018	^[9]	Jun. 27, 2017	^[6]	Jun. 27, 2017	^[6]
Shares \| shares		426,866	^[9]	426,866	^[9]	432,240	^[6]	432,240	^[6]
Drug Discovery & Development \| Rocket Pharmaceuticals, Ltd. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,500	^[2],[9]			$ 1,500	^[1],[6]
Total investments at fair value		$ 18	^[9]			$ 21	^[6]
Acquisition Date		Aug. 22, 2007	^[9]	Aug. 22, 2007	^[9]	Aug. 22, 2007	^[6]	Aug. 22, 2007	^[6]
Shares \| shares		944	^[9]	944	^[9]	944	^[6]	944	^[6]
Drug Discovery & Development \| Savara, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 203	^[2],[9]			$ 202	^[1],[6]
Total investments at fair value		$ 17	^[9]			$ 14	^[6]
Acquisition Date		Aug. 11, 2015	^[9]	Aug. 11, 2015	^[9]	Aug. 11, 2015	^[6]	Aug. 11, 2015	^[6]
Shares \| shares		11,119	^[9]	11,119	^[9]	11,119	^[6]	11,119	^[6]
Drug Discovery & Development \| Tricida, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 863	^[2],[9]			$ 863	^[1],[6]
Total investments at fair value		$ 11	^[9]			$ 658	^[6]
Acquisition Date		Feb. 28, 2018	^[9]	Feb. 28, 2018	^[9]	Feb. 28, 2018	^[6]	Feb. 28, 2018	^[6]
Shares \| shares		68,816	^[9]	68,816	^[9]	68,816	^[6]	68,816	^[6]
Drug Discovery & Development \| Tricida, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 280	^[2],[9]			$ 280	^[1],[6]
Total investments at fair value		$ 1	^[9]			$ 20	^[6]
Acquisition Date		Mar. 27, 2019	^[9]	Mar. 27, 2019	^[9]	Mar. 27, 2019	^[6]	Mar. 27, 2019	^[6]
Shares \| shares		31,352	^[9]	31,352	^[9]	31,352	^[6]	31,352	^[6]
Drug Discovery & Development \| Concert Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,367	^[2],[9],[23]			$ 1,367	^[1],[4],[6]
Total investments at fair value		$ 413	^[9],[23]			$ 223	^[4],[6]
Acquisition Date		Feb. 13, 2019	^[9]	Feb. 13, 2019	^[9]	Feb. 13, 2019	^[6]	Feb. 13, 2019	^[6]
Shares \| shares		70,796	^[9],[23]	70,796	^[9],[23]	70,796	^[4],[6]	70,796	^[4],[6]
Drug Discovery & Development \| Concert Pharmaceuticals, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[4],[6]					$ 178
Total investments at fair value	^[4],[6]					$ 3
Acquisition Date	^[6]					Jun. 08, 2017		Jun. 08, 2017
Shares \| shares	^[4],[6]					61,273		61,273
Drug Discovery & Development \| Gritstone Bio, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2027-07		2027-07
Investment Interest Rate Floor	^[7]	7.15%		7.15%
Investment Interest Rate Paid in Kind	^[7]	2.00%		2.00%
Principal Amount	^[8],[11]	$ 15,113
Investment cost	^[2],[8],[11]	15,109
Total investments at fair value	^[8],[11]	$ 15,109
Drug Discovery & Development \| Gritstone Bio, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	5.75%		5.75%
Drug Discovery & Development \| Gritstone Bio, Inc. \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	8.65%		8.65%
Drug Discovery & Development \| Gritstone Bio, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[7]	3.15%		3.15%
Drug Discovery & Development \| Gritstone Bio, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[9]	$ 1,000
Total investments at fair value	^[9]	$ 1,527
Acquisition Date	^[9]	Oct. 26, 2022		Oct. 26, 2022
Shares \| shares	^[9]	442,477		442,477
Drug Discovery & Development \| Dare Biosciences, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,000	^[2],[9]			$ 1,000	^[1],[6]
Total investments at fair value		$ 11	^[9]			$ 27	^[6]
Acquisition Date		Jan. 08, 2015	^[9]	Jan. 08, 2015	^[9]	Jan. 08, 2015	^[6]	Jan. 08, 2015	^[6]
Shares \| shares		13,550	^[9]	13,550	^[9]	13,550	^[6]	13,550	^[6]
Drug Discovery & Development \| Applied Molecular Transport \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 42	^[2],[9],[23]			$ 42	^[1],[4],[6]
Total investments at fair value		$ 0	^[9],[23]			$ 14	^[4],[6]
Acquisition Date		Apr. 06, 2021	^[9]	Apr. 06, 2021	^[9]	Apr. 06, 2021	^[6]	Apr. 06, 2021	^[6]
Shares \| shares		1,000	^[9],[23]	1,000	^[9],[23]	1,000	^[4],[6]	1,000	^[4],[6]
Drug Discovery & Development \| Avalo Therapeutics Inc P K Cerecor Inc \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,000	^[2],[9]			$ 1,000	^[1],[6]
Total investments at fair value		$ 50	^[9]			$ 202	^[6]
Acquisition Date		Aug. 19, 2014	^[9]	Aug. 19, 2014	^[9]	Aug. 19, 2014	^[6]	Aug. 19, 2014	^[6]
Shares \| shares		9,924	^[9]	9,924	^[9]	119,087	^[6]	119,087	^[6]
Drug Discovery & Development \| Albireo Pharma, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date						2024-07		2024-07
Investment Interest Rate Floor	^[12]					9.15%		9.15%
Principal Amount	^[4],[15]					$ 10,000
Investment cost	^[1],[4],[15]					10,229
Total investments at fair value	^[4],[15]					$ 10,268
Drug Discovery & Development \| Albireo Pharma, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[12]					6.95%		6.95%
Drug Discovery & Development \| Albireo Pharma, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[12]					5.90%		5.90%
Drug Discovery & Development \| Albireo Pharma, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,000	^[2],[9],[23]			$ 1,000	^[1],[4],[6]
Total investments at fair value		$ 540	^[9],[23]			$ 582	^[4],[6]
Acquisition Date		Sep. 14, 2020	^[9]	Sep. 14, 2020	^[9]	Sep. 14, 2020	^[6]	Sep. 14, 2020	^[6]
Shares \| shares		25,000	^[9],[23]	25,000	^[9],[23]	25,000	^[4],[6]	25,000	^[4],[6]
Drug Discovery & Development \| Albireo Pharma, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 61	^[2],[9],[23]			$ 61	^[1],[4],[6]
Total investments at fair value		$ 31	^[9],[23]			$ 42	^[4],[6]
Acquisition Date		Jun. 08, 2020	^[9]	Jun. 08, 2020	^[9]	Jun. 08, 2020	^[6]	Jun. 08, 2020	^[6]
Shares \| shares		5,311	^[9],[23]	5,311	^[9],[23]	5,311	^[4],[6]	5,311	^[4],[6]
Drug Discovery & Development \| Aldeyra Therapeutics, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-10		2024-10		2023-10		2023-10
Investment Interest Rate Floor		8.60%	^[7]	8.60%	^[7]	8.60%	^[12]	8.60%	^[12]
Principal Amount		$ 15,000	^[13]			$ 15,000
Investment cost		15,879	^[2],[13]			15,639	^[1]
Total investments at fair value		$ 15,974	^[13]			$ 15,653
Drug Discovery & Development \| Aldeyra Therapeutics, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		8.90%	^[7]	8.90%	^[7]	6.95%	^[12]	6.95%	^[12]
Drug Discovery & Development \| Aldeyra Therapeutics, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		3.10%	^[7]	3.10%	^[7]	3.10%	^[12]	3.10%	^[12]
Drug Discovery & Development \| Applied Genetic Technologies Corporation \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date						2024-04		2024-04
Investment Interest Rate Floor	^[12]					9.75%		9.75%
Principal Amount						$ 20,000
Investment cost	^[1]					20,416
Total investments at fair value						$ 20,339
Drug Discovery & Development \| Applied Genetic Technologies Corporation \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[12]					6.95%		6.95%
Drug Discovery & Development \| Applied Genetic Technologies Corporation \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[12]					6.50%		6.50%
Drug Discovery & Development \| Aveo Pharmaceuticals, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-09		2024-09		2024-09		2024-09
Investment Interest Rate Floor		9.65%	^[7]	9.65%	^[7]	9.65%	^[12]	9.65%	^[12]
Principal Amount		$ 40,000	^[13],[25]			$ 40,000	^[15],[31]
Investment cost		41,644	^{[2],[13],[25]}			40,842	^{[1],[15],[31]}
Total investments at fair value		$ 43,183	^[13],[25]			$ 40,776	^[15],[31]
Drug Discovery & Development \| Aveo Pharmaceuticals, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		6.95%	^[7]	6.95%	^[7]	6.95%	^[12]	6.95%	^[12]
Drug Discovery & Development \| Aveo Pharmaceuticals, Inc. \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	15.00%		15.00%
Drug Discovery & Development \| Aveo Pharmaceuticals, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		6.40%	^[7]	6.40%	^[7]	6.40%	^[12]	6.40%	^[12]
Drug Discovery & Development \| Aveo Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,715	^[2],[9]			$ 1,715	^[1],[6]
Total investments at fair value		$ 2,843	^[9]			$ 892	^[6]
Acquisition Date		Jul. 31, 2011	^[9]	Jul. 31, 2011	^[9]	Jul. 31, 2011	^[6]	Jul. 31, 2011	^[6]
Shares \| shares		190,179	^[9]	190,179	^[9]	190,179	^[6]	190,179	^[6]
Drug Discovery & Development \| Acacia Pharma Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 304	^{[2],[23],[24]}			$ 305	^{[1],[4],[5],[6]}
Total investments at fair value		$ 0	^[23],[24]			$ 6	^[4],[5],[6]
Acquisition Date		Jun. 29, 2018	^[9]	Jun. 29, 2018	^[9]	Jun. 29, 2018	^[6]	Jun. 29, 2018	^[6]
Shares \| shares		201,330	^[23],[24]	201,330	^[23],[24]	201,330	^[4],[5],[6]	201,330	^[4],[5],[6]
Drug Discovery & Development \| ADMA Biologics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 166	^[2],[9]			$ 295	^[1],[6]
Total investments at fair value		$ 10	^[9]			$ 1	^[6]
Acquisition Date		Feb. 24, 2014	^[9]	Feb. 24, 2014	^[9]	Dec. 21, 2012	^[6]	Dec. 21, 2012	^[6]
Shares \| shares		58,000	^[9]	58,000	^[9]	89,750	^[6]	89,750	^[6]
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-10		2026-10		2026-10		2026-10
Investment Interest Rate Floor		8.95%	^[7]	8.95%	^[7]	8.95%	^[12]	8.95%	^[12]
Principal Amount		$ 81,725	^{[8],[13],[18],[19],[23]}			$ 50,000	^[4],[32]
Investment cost		81,631	^{[2],[8],[13],[18],[19],[23]}			49,542	^[1],[4],[32]
Total investments at fair value		$ 78,074	^{[8],[13],[18],[19],[23]}			$ 48,859	^[4],[32]
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		5.31%	^[7]	5.31%	^[7]	5.82%	^[12]	5.82%	^[12]
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	10.70%		10.70%
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		5.70%	^[7]	5.70%	^[7]	5.70%	^[12]	5.70%	^[12]
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^{[2],[9],[19],[23]}	$ 4,165
Total investments at fair value	^{[9],[19],[23]}	$ 9,797
Acquisition Date	^[9]	May 09, 2022		May 09, 2022
Shares \| shares	^{[9],[19],[23]}	127,021		127,021
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 880	^{[2],[9],[18],[19],[23]}			$ 681	^[1],[4],[6]
Total investments at fair value		$ 1,590	^{[9],[18],[19],[23]}			$ 142	^[4],[6]
Acquisition Date		Sep. 25, 2020	^[9]	Sep. 25, 2020	^[9]	Sep. 25, 2020	^[6]	Sep. 25, 2020	^[6]
Shares \| shares		40,396	^{[9],[18],[19],[23]}	40,396	^{[9],[18],[19],[23]}	15,541	^[4],[6]	15,541	^[4],[6]
Drug Discovery & Development \| Brickell Biotech, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 119	^[2],[9]			$ 119	^[1],[6]
Total investments at fair value		$ 0	^[9]			$ 0	^[6]
Acquisition Date		Feb. 18, 2016	^[9]	Feb. 18, 2016	^[9]	Feb. 18, 2016	^[6]	Feb. 18, 2016	^[6]
Shares \| shares		200	^[9]	200	^[9]	9,005	^[6]	9,005	^[6]
Drug Discovery & Development \| Bicycle Therapeutics PLC \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2025-07		2025-07		2024-10		2024-10
Investment Interest Rate Floor		8.05%	^[7]	8.05%	^[7]	8.85%	^[12]	8.85%	^[12]
Principal Amount		$ 11,500	^{[13],[18],[23],[24]}			$ 24,000	^{[3],[4],[5],[15],[32]}
Investment cost		11,757	^{[2],[13],[18],[23],[24]}			24,271	^{[1],[3],[4],[5],[15],[32]}
Total investments at fair value		$ 11,435	^{[13],[18],[23],[24]}			$ 24,454	^{[3],[4],[5],[15],[32]}
Drug Discovery & Development \| Bicycle Therapeutics PLC \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		5.00%	^[7]	5.00%	^[7]	5.00%	^[12]	5.00%	^[12]
Drug Discovery & Development \| Bicycle Therapeutics PLC \| Senior Secured Debt \| Cap rate
Investment Holdings [Line Items]
Interest Rate and Floor	^[7]	9.05%		9.05%
Drug Discovery & Development \| Bicycle Therapeutics PLC \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		4.55%	^[7]	4.55%	^[7]	5.60%	^[12]	5.60%	^[12]
Drug Discovery & Development \| Bicycle Therapeutics PLC \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,871	^{[2],[9],[23],[24]}			$ 1,871	^{[1],[4],[5],[6]}
Total investments at fair value		$ 2,904	^{[9],[23],[24]}			$ 5,971	^[4],[5],[6]
Acquisition Date		Oct. 05, 2020	^[9]	Oct. 05, 2020	^[9]	Oct. 05, 2020	^[6]	Oct. 05, 2020	^[6]
Shares \| shares		98,100	^{[9],[23],[24]}	98,100	^{[9],[23],[24]}	98,100	^[4],[5],[6]	98,100	^[4],[5],[6]
Drug Discovery & Development \| BiomX, INC \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2025-09		2025-09		2025-09		2025-09
Investment Interest Rate Floor		8.95%	^[7]	8.95%	^[7]	8.95%	^[12]	8.95%	^[12]
Principal Amount		$ 9,000	^{[13],[23],[24]}			$ 9,000	^[4],[5],[15]
Investment cost		9,174	^{[2],[13],[23],[24]}			8,980	^{[1],[4],[5],[15]}
Total investments at fair value		$ 9,052	^{[13],[23],[24]}			$ 8,980	^[4],[5],[15]
Drug Discovery & Development \| BiomX, INC \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		6.55%	^[7]	6.55%	^[7]	6.55%	^[12]	6.55%	^[12]
Drug Discovery & Development \| BiomX, INC \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		5.70%	^[7]	5.70%	^[7]	5.70%	^[12]	5.70%	^[12]
Drug Discovery & Development \| BridgeBio Pharma, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-11		2026-11		2026-11		2026-11
Principal Amount		$ 37,312	^{[11],[17],[18]}			$ 38,000
Investment Interest Rate Paid in Cash		9.00%	^[7]	9.00%	^[7]	9.00%	^[12]	9.00%	^[12]
Investment cost		$ 37,039	^{[2],[11],[17],[18]}			$ 37,462	^[1]
Total investments at fair value		$ 33,344	^{[11],[17],[18]}			$ 37,462
Drug Discovery & Development \| BridgeBio Pharma, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		2.00%	^[7]	2.00%	^[7]	2.00%	^[12]	2.00%	^[12]
Drug Discovery & Development \| BridgeBio Pharma, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 2,255	^[2],[9]			$ 2,255	^[1],[6]
Total investments at fair value		$ 1,763	^[9]			$ 3,859	^[6]
Acquisition Date		Jun. 21, 2018	^[9]	Jun. 21, 2018	^[9]	Jun. 21, 2018	^[6]	Jun. 21, 2018	^[6]
Shares \| shares		231,329	^[9]	231,329	^[9]	231,329	^[6]	231,329	^[6]
Drug Discovery & Development \| Cellarity, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2026-06		2026-06		2026-06		2026-06
Investment Interest Rate Floor		8.95%	^[7]	8.95%	^[7]	8.95%	^[12]	8.95%	^[12]
Principal Amount		$ 30,000	^[17],[25]			$ 30,000	^[31]
Investment cost		29,841	^{[2],[17],[25]}			29,422	^[1],[31]
Total investments at fair value		$ 30,097	^[17],[25]			$ 29,422	^[31]
Drug Discovery & Development \| Cellarity, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		3.75%	^[7]	3.75%	^[7]	3.75%	^[12]	3.75%	^[12]
Drug Discovery & Development \| Cellarity, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		5.70%	^[7]	5.70%	^[7]	5.70%	^[12]	5.70%	^[12]
Drug Discovery & Development \| Cellarity, Inc. \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost		$ 287	^[2],[25]			$ 287	^[1],[31]
Total investments at fair value		$ 318	^[25]			$ 287	^[31]
Acquisition Date		Dec. 08, 2021	^[9]	Dec. 08, 2021	^[9]	Dec. 08, 2021	^[6]	Dec. 08, 2021	^[6]
Shares \| shares		100,000	^[25]	100,000	^[25]	100,000	^[31]	100,000	^[31]
Drug Discovery & Development \| Center for Breakthrough Medicines Holdings, LLC [Member] \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date						2023-05		2023-05
Investment Interest Rate Floor	^[12]					8.75%		8.75%
Principal Amount						$ 5,000
Investment cost	^[1]					5,005
Total investments at fair value						$ 5,005
Drug Discovery & Development \| Center for Breakthrough Medicines Holdings, LLC [Member] \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor	^[12]					7.50%		7.50%
Drug Discovery & Development \| Center for Breakthrough Medicines Holdings, LLC [Member] \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate	^[12]					5.50%		5.50%
Drug Discovery & Development \| Century Therapeutics, Inc. \| Senior Secured Debt
Investment Holdings [Line Items]
Maturity Date		2024-04		2024-04		2024-04		2024-04
Investment Interest Rate Floor		9.55%	^[7]	9.55%	^[7]	9.55%	^[12]	9.55%	^[12]
Principal Amount		$ 10,000	^[13]			$ 10,000	^[15]
Investment cost		10,235	^[2],[13]			10,075	^[1],[15]
Total investments at fair value		$ 10,292	^[13]			$ 10,361	^[15]
Drug Discovery & Development \| Century Therapeutics, Inc. \| Senior Secured Debt \| Exit Fee Interest Income
Investment Holdings [Line Items]
Interest Rate and Floor		3.95%	^[7]	3.95%	^[7]	3.95%	^[12]	3.95%	^[12]
Drug Discovery & Development \| Century Therapeutics, Inc. \| Senior Secured Debt \| Prime Rate
Investment Holdings [Line Items]
Investment Basis Spread Variable Rate		6.30%	^[7]	6.30%	^[7]	6.30%	^[12]	6.30%	^[12]
Drug Discovery & Development \| Century Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 37	^[2],[9]			$ 37	^[1],[6]
Total investments at fair value		$ 3	^[9]			$ 64	^[6]
Acquisition Date		Sep. 14, 2020	^[9]	Sep. 14, 2020	^[9]	Sep. 14, 2020	^[6]	Sep. 14, 2020	^[6]
Shares \| shares		16,112	^[9]	16,112	^[9]	16,112	^[6]	16,112	^[6]
Drug Discovery & Development \| Chemocentryx Inc One \| Senior Secured Debt